Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Renal and urinary disorders

  • 590 clinical trials
  • 228 recruiting
  • 298 conditions
  • 26 countries

Conditions in this area

298 conditions with trials, the busiest first

Chronic kidney disease67Bladder cancer56Transitional cell carcinoma48Renal cell carcinoma43Bladder transitional cell carcinoma34IgA nephropathy25Acute kidney injury21Non-small cell lung cancer20Urinary tract infection19Lupus nephritis18Paroxysmal nocturnal haemoglobinuria17Clear cell renal cell carcinoma16Breast cancer15End stage renal disease13Metastatic renal cell carcinoma13Colorectal cancer12Congenital cystic kidney disease12Hepatocellular carcinoma12Malignant melanoma12Endometrial cancer11Kidney transplant rejection11Nephrotic syndrome11Ovarian cancer11Glomerulonephritis membranous10+274

Clinical trials in Renal and urinary disorders

590 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

590 clinical trials

Type 2 diabetes mellitus+1

Recruiting

Study of once weekly subcutaneous zenagamtide versus placebo in adults with type 2 diabetes and chronic kidney disease on basal insulin

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Zenagamtide
  • Sponsor:Novo Nordisk A/S

Urinary incontinence+1

Recruiting

Orforglipron for stress urinary incontinence in women with obesity or overweight

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years
  • Substances:Orforglipron hemicalcium
  • Sponsor:Eli Lilly & Co.

Chronic kidney disease

Recruiting

Phase III Randomized Study of Balcinrenone and Dapagliflozin Versus Dapagliflozin on Renal and Cardiovascular Outcomes in Patients with Chronic Kidney Disease Stage 3b‑4

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Balcinrenone
  • Sponsor:AstraZeneca AB

Chronic kidney disease

Recruiting

Randomized Phase III trial of elecoglipron plus dapagliflozin on kidney outcomes and mortality in adults with chronic kidney disease

Registered drug
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:AZD5004
  • Sponsor:AstraZeneca AB

Renal disorder

Recruiting

BI 764198 in Adults and Adolescents with Proteinuric Kidney Diseases

Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Sponsor:Boehringer Ingelheim Espana S.A.

Bladder transitional cell carcinoma+1

Recruiting

A study of loxo-435, enfortumab vedotin, and pembrolizumab in adults with advanced or metastatic bladder cancer

Registered drug
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Enfortumab Vedotin
  • Sponsor:Eli Lilly & Co.

Focal segmental glomerulosclerosis

Recruiting

A study to evaluate the effects of BI 764198 in adults and adolescents with focal segmental glomerulosclerosis (FSGS)

Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Sponsor:Boehringer Ingelheim Espana S.A.

Bladder transitional cell carcinoma

Recruiting

Study of nadofaragene firadenovec alone or with gemcitabine, docetaxel or pembrolizumab in adults with non-muscle invasive bladder cancer who did not respond to BCG therapy

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:Ferring Pharmaceuticals A/S

Chronic kidney disease+1

Recruiting

Study on the Effects of Baxdrostat and Dapagliflozin in Adults with Chronic Kidney Disease and High Blood Pressure

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Baxdrostat
  • Sponsor:AstraZeneca AB

Bladder transitional cell carcinoma

Recruiting

Study of Nadofaragene Firadenovec for Adults with Intermediate Risk Non-Muscle Invasive Bladder Cancer

InvestigationalNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Nadofaragene firadenovec
  • Sponsor:Ferring Pharmaceuticals A/S

Nephrotic syndrome

Recruiting

Study on Rituximab for Adults with Relapsing Steroid-Sensitive Nephrotic Syndrome

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Rituximab
  • Sponsor:Medical University Of Lodz

Pyelonephritis acute

Recruiting

Study on the Safety and Absorption of Meropenem and Vaborbactam in Children with Complicated Urinary Tract Infections

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:0–17 years
  • Substances:Meropenem
  • Sponsor:Menarini Ricerche S.p.A.

Substances studied in this area

The therapies tested most often in Renal and urinary disorders trials.

Pembrolizumab55 clinical trialsNivolumab36 clinical trialsDapagliflozin24 clinical trialsMycophenolate Mofetil23 clinical trialsCabozantinib22 clinical trialsCisplatin22 clinical trialsGemcitabine21 clinical trialsIpilimumab20 clinical trialsSodium Chloride18 clinical trials
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.